FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3180808600> ?p ?o ?g. }

• W3180808600 endingPage "2905" @default.
• W3180808600 startingPage "2899" @default.
• W3180808600 abstract "To evaluate the administration regimen of ceftazidime/avibactam (CZA) for bloodstream infections caused by Enterobacteriaceae and Pseudomonas aeruginosa.The minimal inhibitory concentrations (MICs) of CZA against Enterobacteriaceae and P. aeruginosa isolated from blood cultures at member hospitals in BRICS (Blood Bacterial Resistant Investigation Collaborative System) in 2019 were determined by broth micro-dilution methodology. A 10,000-patient Monte Carlo simulation (MCS) was used to calculate the probability of target attainment (PTA) and cumulative fraction of response (CFR) for different CZA dosage regimens to evaluate their efficacies and optimize the best initial dosage regimen.Altogether, 6487 Enterobacteriaceae and P. aeruginosa strains were isolated from the blood cultures. The overall CZA resistance rate was 2.31%, of which the Enterobacteriaceae and P. aeruginosa rates were 1.57% and 14.29%, respectively. The MCS showed that the greater the MIC value, the worse the therapeutic effect. When the CZA MIC was ≤8 mg/L, the standard dose (2.5g iv q8h) achieved 90% PTA in the subset of patients with creatinine clearance (CrCl) values from 51 to 120 mL/min. Although the high-dose regimen (3.75g iv q8h) achieved 90% PTA in patients with CrCl values from 121 to 190 mL/min, implementing the low-dose regimen (1.25g iv q8h) was also effective for patients in the 51-89 mL/min CrCl range. Generally, the high-dose regimen (3.75g iv q8h) reached 90% CFR against all of the strains. Conversely, in patients with CrCl values of 121-190 mL/min, the standard dose (2.5g iv q8h) failed to reach 90% CFR against some Enterobacteriaceae members and P. aeruginosa. When the dose was reduced to the low-dose regimen (1.25g iv q8h), no patients reached 90% CFR against some Enterobacteriaceae members and P. aeruginosa.CZA has good antibacterial activity against Enterobacteriaceae and P. aeruginosa in bloodstream infections. Clinicians could make individualized treatment regimens in accordance with the sensitivity of the strains and the level of renal function in their patients to best predict the drug-related clinical responses." @default.
• W3180808600 created "2021-07-19" @default.
• W3180808600 creator A5003896541 @default.
• W3180808600 creator A5004032681 @default.
• W3180808600 creator A5013532180 @default.
• W3180808600 creator A5025761377 @default.
• W3180808600 creator A5026563221 @default.
• W3180808600 creator A5027217113 @default.
• W3180808600 creator A5028304285 @default.
• W3180808600 creator A5036099783 @default.
• W3180808600 creator A5047371223 @default.
• W3180808600 creator A5055916244 @default.
• W3180808600 creator A5071205359 @default.
• W3180808600 creator A5079509032 @default.
• W3180808600 creator A5084650592 @default.
• W3180808600 creator A5088346632 @default.
• W3180808600 date "2021-07-01" @default.
• W3180808600 modified "2023-09-24" @default.
• W3180808600 title "Evaluation of Ceftazidime/Avibactam Administration in Enterobacteriaceae and Pseudomonas aeruginosa Bloodstream Infections by Monte Carlo Simulation" @default.
• W3180808600 cites W2018229558 @default.
• W3180808600 cites W2056317617 @default.
• W3180808600 cites W2097533517 @default.
• W3180808600 cites W2101004558 @default.
• W3180808600 cites W2131370687 @default.
• W3180808600 cites W2137527487 @default.
• W3180808600 cites W2230555963 @default.
• W3180808600 cites W2742813652 @default.
• W3180808600 cites W2767965830 @default.
• W3180808600 cites W2897055654 @default.
• W3180808600 cites W2909784981 @default.
• W3180808600 cites W2962639072 @default.
• W3180808600 cites W2969215914 @default.
• W3180808600 cites W2995182581 @default.
• W3180808600 cites W3016555942 @default.
• W3180808600 cites W3097875948 @default.
• W3180808600 cites W4253431854 @default.
• W3180808600 doi "https://doi.org/10.2147/dddt.s309825" @default.
• W3180808600 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8275101" @default.
• W3180808600 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34262257" @default.
• W3180808600 hasPublicationYear "2021" @default.
• W3180808600 type Work @default.
• W3180808600 sameAs 3180808600 @default.
• W3180808600 citedByCount "2" @default.
• W3180808600 countsByYear W31808086002022 @default.
• W3180808600 countsByYear W31808086002023 @default.
• W3180808600 crossrefType "journal-article" @default.
• W3180808600 hasAuthorship W3180808600A5003896541 @default.
• W3180808600 hasAuthorship W3180808600A5004032681 @default.
• W3180808600 hasAuthorship W3180808600A5013532180 @default.
• W3180808600 hasAuthorship W3180808600A5025761377 @default.
• W3180808600 hasAuthorship W3180808600A5026563221 @default.
• W3180808600 hasAuthorship W3180808600A5027217113 @default.
• W3180808600 hasAuthorship W3180808600A5028304285 @default.
• W3180808600 hasAuthorship W3180808600A5036099783 @default.
• W3180808600 hasAuthorship W3180808600A5047371223 @default.
• W3180808600 hasAuthorship W3180808600A5055916244 @default.
• W3180808600 hasAuthorship W3180808600A5071205359 @default.
• W3180808600 hasAuthorship W3180808600A5079509032 @default.
• W3180808600 hasAuthorship W3180808600A5084650592 @default.
• W3180808600 hasAuthorship W3180808600A5088346632 @default.
• W3180808600 hasBestOaLocation W31808086002 @default.
• W3180808600 hasConcept C104317684 @default.
• W3180808600 hasConcept C126322002 @default.
• W3180808600 hasConcept C176947019 @default.
• W3180808600 hasConcept C185592680 @default.
• W3180808600 hasConcept C2775933652 @default.
• W3180808600 hasConcept C2776968632 @default.
• W3180808600 hasConcept C2777637488 @default.
• W3180808600 hasConcept C2778910516 @default.
• W3180808600 hasConcept C2781413609 @default.
• W3180808600 hasConcept C501593827 @default.
• W3180808600 hasConcept C523546767 @default.
• W3180808600 hasConcept C54355233 @default.
• W3180808600 hasConcept C547475151 @default.
• W3180808600 hasConcept C55493867 @default.
• W3180808600 hasConcept C71924100 @default.
• W3180808600 hasConcept C86803240 @default.
• W3180808600 hasConcept C89423630 @default.
• W3180808600 hasConceptScore W3180808600C104317684 @default.
• W3180808600 hasConceptScore W3180808600C126322002 @default.
• W3180808600 hasConceptScore W3180808600C176947019 @default.
• W3180808600 hasConceptScore W3180808600C185592680 @default.
• W3180808600 hasConceptScore W3180808600C2775933652 @default.
• W3180808600 hasConceptScore W3180808600C2776968632 @default.
• W3180808600 hasConceptScore W3180808600C2777637488 @default.
• W3180808600 hasConceptScore W3180808600C2778910516 @default.
• W3180808600 hasConceptScore W3180808600C2781413609 @default.
• W3180808600 hasConceptScore W3180808600C501593827 @default.
• W3180808600 hasConceptScore W3180808600C523546767 @default.
• W3180808600 hasConceptScore W3180808600C54355233 @default.
• W3180808600 hasConceptScore W3180808600C547475151 @default.
• W3180808600 hasConceptScore W3180808600C55493867 @default.
• W3180808600 hasConceptScore W3180808600C71924100 @default.
• W3180808600 hasConceptScore W3180808600C86803240 @default.
• W3180808600 hasConceptScore W3180808600C89423630 @default.
• W3180808600 hasLocation W31808086001 @default.
• W3180808600 hasLocation W31808086002 @default.
• W3180808600 hasLocation W31808086003 @default.

• next